The AS01E-adjuvanted RSV prefusion F protein vaccine (RSVPreF3 OA) showed 62.9% cumulative efficacy against RSV-related lower respiratory tract disease (RSV-LRTD) over three consecutive respiratory syncytial virus (RSV) seasons in adults aged 60 years and above.
Both single-dose and revaccination after one year demonstrated comparable efficacy profiles, although efficacy gradually decreased over time.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
